In addition to its role in BER, PARP and PAR are important targets in recent and emerging cancer therapies due to the demonstrated synthetic lethality of PARP inhibition in cells with BRCA1/BRCA2 mutations or deletions [12,13]. This evidence concerns the gene BRCA2 and cancer.